---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-283294"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2025-11-14T23:59:59+00:00"
generated_at: "2026-05-16T19:47:26.867641+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eledon reports Q3 net loss $17.5M; Phase 2 BESTOW positive; raises $57.5M

## Summary
- Net loss $17.5M ($0.21/shr) vs net income $77M (incl $96.4M warrant gain) in Q3 2024.
- Cash & investments $93.4M at Sep 30, down from $140.2M at Dec 31, 2024.
- Phase 2 BESTOW: tegoprubart showed favorable safety, eGFR ~69 at 12 months; plans Phase 3 in 2026.
- Completed $57.5M public offering on Nov 13, net proceeds ~$53.6M to advance transplant programs.
- Anticipates FDA guidance on Phase 3 trial design for kidney transplantation in 2026.

## SEC filing metadata
- accession: 0001193125-25-283294
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2025-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000119312525283294/0001193125-25-283294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000119312525283294/eldn-20251114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-283294
- JSON: https://secwatch.observer/filing/0001193125-25-283294.json
- Plain text: https://secwatch.observer/filing/0001193125-25-283294.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.